Revenues of Bioxytran Inc's Suppliers, deteriorated by -2.45 % compared to the same quarter a year ago, sequentially sales grew by 2.25 %, while their net margin rose to 13.67 % year on year, Bioxytran Inc's Suppliers improved sequentially profit margin to 2.25 %,
Bioxytran Inc's Suppliers realized a deteriorated in sales by -2.45 % compared to the same quarter a year ago, sequentially sales grew by 2.25 %, while their net margin rose to 13.67 % year on year, Bioxytran Inc's Suppliers improved sequentially profit margin to 13.67 %,
The company requires suppliers to maintain traceable records on animal origin, health, feed, and care to ensure compliance with relevant laws and regulations. Camel whole blood is collected in individual pre-sanitized containers and shipped to a separation facility. Animals undergo live inspection prior to blood collection. The company has validated processes to remove potential pathogens, including bacteria and viruses, from raw materials. The manufacturing process for BXT-25 includes four main steps: hemoglobin separation, purification, polymerization/size selection, and co-polymer synthesis. Camel blood is aseptically collected, plasma is removed, and hemoglobin is purified using anion exchange chromatography. The hemoglobin is then stabilized with a cross-linking agent, sized to eliminate higher molecular weight components, and synthesized with a co-polymer. The final product is sterilized and filled into sterile bags. The company intends to license BXT-25 to large pharmaceutical companies for clinical trials and distribution, utilizing third parties for marketing and sales.
Bioxytran Inc's Comment on Supply Chain
The company requires suppliers to maintain traceable records on animal origin, health, feed, and care to ensure compliance with relevant laws and regulations. Camel whole blood is collected in individual pre-sanitized containers and shipped to a separation facility. Animals undergo live inspection prior to blood collection. The company has validated processes to remove potential pathogens, including bacteria and viruses, from raw materials. The manufacturing process for BXT-25 includes four main steps: hemoglobin separation, purification, polymerization/size selection, and co-polymer synthesis. Camel blood is aseptically collected, plasma is removed, and hemoglobin is purified using anion exchange chromatography. The hemoglobin is then stabilized with a cross-linking agent, sized to eliminate higher molecular weight components, and synthesized with a co-polymer. The final product is sterilized and filled into sterile bags. The company intends to license BXT-25 to large pharmaceutical companies for clinical trials and distribution, utilizing third parties for marketing and sales.
BIXT's Suppliers Net Income grew by
BIXT's Suppliers Net margin grew in Q2 to
89.14 %
13.67 %
BIXT's Suppliers Net Income grew by 89.14 %
BIXT's Suppliers Net margin grew in Q2 to 13.67 %
Bioxytran Inc's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Bioxytran Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Bioxytran Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
9.37 % 